Arrayit Diagnostics Licenses Ovarian Cancer Biomarkers from Wayne State U | GenomeWeb

NEW YORK (GenomeWeb News) – Arrayit Diagnostics said today that it has exclusively licensed ovarian cancer biomarker intellectual property from Wayne State University.

Under the agreement, Houston-based Arrayit Diagnostics, a majority-owned subsidiary of Sunnyvale, Calif.-based Arrayit Corporation, gains exclusive worldwide rights to develop and commercialize a microarray-based diagnostic test using the biomarkers, which were developed by WSU researchers Michael Tainsky, Sorin Draghici, and Madhumita Chatterjee.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.